MED23抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P00244(CCK Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

The MED23 antibody is a research tool designed to target the MED23 protein, a critical subunit of the Mediator complex—a multi-protein assembly essential for regulating RNA polymerase II-dependent transcription. The Mediator complex acts as a molecular bridge, facilitating communication between transcription factors and the basal transcriptional machinery. MED23 specifically interacts with transcription activators, such as serum response factor (SRF) and Elk-1. to modulate gene expression involved in cell growth, differentiation, and stress responses.

MED23 plays a role in various cellular processes, including signal transduction, development, and oncogenesis. Dysregulation of MED23 has been linked to diseases like cancer, intellectual disabilities, and autoimmune disorders, making it a focus of biomedical research. Antibodies against MED23 enable scientists to study its expression, localization, and interactions via techniques like Western blotting, immunofluorescence, chromatin immunoprecipitation (ChIP), and co-immunoprecipitation (Co-IP).

These antibodies are typically validated for specificity and sensitivity, often using knockout cell lines or siRNA-mediated knockdown controls. Researchers utilize MED23 antibodies to explore transcriptional mechanisms, identify MED23-associated pathways, and assess its role in disease contexts. Commercial MED23 antibodies are commonly raised in hosts like rabbits or mice, with options for monoclonal or polyclonal formats tailored to diverse experimental needs.